News | September 05, 2024
Emcure Pharmaceuticals launches solution for menopause wellness ‘Arth’ in India
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
Revolutionary technology will further boost OneSource’s scientific services offerings
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Subscribe To Our Newsletter & Stay Updated
